NASDAQ:GLYC GlycoMimetics (GLYC) Stock Price, News & Analysis → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Free GLYC Stock Alerts $2.80 +0.24 (+9.38%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$2.58▼$2.8750-Day Range$2.55▼$3.4952-Week Range$1.11▼$3.53Volume468,188 shsAverage Volume343,215 shsMarket Capitalization$180.29 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get GlycoMimetics alerts: Email Address GlycoMimetics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside257.1% Upside$10.00 Price TargetShort InterestBearish2.42% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment-0.06Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.60) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector286th out of 947 stocksPharmaceutical Preparations Industry136th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingGlycoMimetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, GlycoMimetics has a forecasted upside of 257.1% from its current price of $2.80.Amount of Analyst CoverageGlycoMimetics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.42% of the outstanding shares of GlycoMimetics have been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in GlycoMimetics has recently increased by 9.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for GlycoMimetics is -0.55. Previous Next 1.1 News and Social Media Coverage News SentimentGlycoMimetics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for GlycoMimetics this week, compared to 1 article on an average week.Search InterestOnly 11 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions55.36% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GlycoMimetics are expected to grow in the coming year, from ($0.60) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About GlycoMimetics Stock (NASDAQ:GLYC)GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Read More GLYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLYC Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comGLYC Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comGLYC Apr 2024 2.500 putMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 16, 2024 | markets.businessinsider.comGlycoMimetics Inc hosts conference call for investorsMarch 16, 2024 | finance.yahoo.comGLYC Apr 2024 5.000 callMarch 16, 2024 | americanbankingnews.comStockNews.com Downgrades GlycoMimetics (NASDAQ:GLYC) to SellMarch 14, 2024 | msn.comImmuneering cancer drug shows initial clinical activity in early-stage trialMarch 13, 2024 | barrons.comPalatin Technologies Inc.March 18, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 13, 2024 | businesswire.comGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024March 10, 2024 | morningstar.comGlycoMimetics Inc GLYCMarch 4, 2024 | finance.yahoo.comPositive Signs As Multiple Insiders Buy GlycoMimetics StockFebruary 26, 2024 | finance.yahoo.comGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceFebruary 26, 2024 | businesswire.comGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceFebruary 23, 2024 | finance.yahoo.comGlycoMimetics, Inc. (GKO.F)February 12, 2024 | finance.yahoo.comGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)January 30, 2024 | seekingalpha.comGlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be RealJanuary 5, 2024 | benzinga.comGlycoMimetics Stock (NASDAQ:GLYC), Analyst Ratings, Price Targets, PredictionsJanuary 4, 2024 | markets.businessinsider.comGlycoMimetics' GMI-1687 Meets Primary Goal In Phase 1a StudyJanuary 4, 2024 | finance.yahoo.comGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687December 30, 2023 | benzinga.comGlycoMimetics Stock (NASDAQ:GLYC) Dividends: History, Yield and DatesDecember 23, 2023 | msn.comCapital One Initiates Coverage of GlycoMimetics (GLYC) with Overweight RecommendationDecember 17, 2023 | finance.yahoo.comRetail investors in GlycoMimetics, Inc. (NASDAQ:GLYC) are its biggest bettors, and their bets paid off as stock gained 23% last weekDecember 12, 2023 | markets.businessinsider.comPromising Outlook for GlycoMimetics’ Uproleselan Drives Buy RatingDecember 10, 2023 | finance.yahoo.comGlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaNovember 9, 2023 | finance.yahoo.comGlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceNovember 7, 2023 | markets.businessinsider.comBuy Rating for GlycoMimetics: Stable Financials and Promising Drug Candidate Uproleselan Drive Positive OutlookSee More Headlines Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2023Today3/18/2024Next Earnings (Confirmed)3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLYC CUSIPN/A CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees38Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+266.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.75% Return on Assets-64.58% Debt Debt-to-Equity RatioN/A Current Ratio8.14 Quick Ratio8.14 Sales & Book Value Annual Sales$80,000.00 Price / Sales2,197.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book3.33Miscellaneous Outstanding Shares64,390,000Free Float59,242,000Market Cap$175.78 million OptionableOptionable Beta2.19 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Harout Semerjian (Age 54)CEO, President & Director Comp: $1.1MMs. Rachel K. King (Age 65)Co-Founder & Director Comp: $226.43kMr. Brian M. Hahn (Age 50)Senior VP & CFO Comp: $748.27kMs. Stephanie R. Irish CPA (Age 53)Vice President of Accounting Mr. Christian B. Dinneen-LongGeneral Counsel & Company SecretaryMr. Bruce Johnson (Age 56)Senior VP & Chief Commercial Officer Dr. Edwin Rock M.D. (Age 63)Ph.D., Senior VP & Chief Medical Officer Mr. Chinmaya Rath (Age 47)Senior VP & Chief Business Officer Mr. Shantha Tyavanagimatt Ph.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsKaryopharm TherapeuticsNASDAQ:KPTIRelmada TherapeuticsNASDAQ:RLMDSpyre TherapeuticsNASDAQ:SYREImmuneeringNASDAQ:IMRXProQR TherapeuticsNASDAQ:PRQRView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Bought 124,861 shares on 3/1/2024Ownership: 1.428%Virtu Financial LLCBought 34,319 shares on 2/26/2024Ownership: 0.053%GSA Capital Partners LLPBought 107,208 shares on 2/16/2024Ownership: 0.312%Bridgeway Capital Management LLCBought 25,000 shares on 2/15/2024Ownership: 0.306%Citadel Advisors LLCBought 10,700 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GLYC Stock Analysis - Frequently Asked Questions Should I buy or sell GlycoMimetics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GLYC shares. View GLYC analyst ratings or view top-rated stocks. What is GlycoMimetics' stock price target for 2024? 2 brokers have issued twelve-month price objectives for GlycoMimetics' stock. Their GLYC share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 257.1% from the stock's current price. View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts. How have GLYC shares performed in 2024? GlycoMimetics' stock was trading at $2.36 on January 1st, 2024. Since then, GLYC stock has increased by 18.6% and is now trading at $2.80. View the best growth stocks for 2024 here. Are investors shorting GlycoMimetics? GlycoMimetics saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 1,560,000 shares, an increase of 9.1% from the February 14th total of 1,430,000 shares. Based on an average daily trading volume, of 336,300 shares, the short-interest ratio is currently 4.6 days. View GlycoMimetics' Short Interest. When is GlycoMimetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our GLYC earnings forecast. How can I listen to GlycoMimetics' earnings call? GlycoMimetics will be holding an earnings conference call on Wednesday, March 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) released its earnings results on Friday, November, 3rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.14). During the same period last year, the company posted ($0.16) earnings per share. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX). Who are GlycoMimetics' major shareholders? GlycoMimetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (1.43%), Goldman Sachs Group Inc. (1.43%), GSA Capital Partners LLP (0.31%), Bridgeway Capital Management LLC (0.31%), Northern Trust Corp (0.17%) and MJP Associates Inc. ADV (0.16%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell. View institutional ownership trends. How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLYC) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.